PierianDx, a St. Louis-based clinical genomic analysis, interpretation and reporting company, acquired Tute Genomics, a genomics software company based in Provo, UT.
The amount of the deal was not disclosed.
The acquisition will further expand PierianDx’s platform to enable personalized medicine for clinical labs. Its cloud-based software platforms for somatic cancer, Clinical Genomicist Workspace (CGW), will be enhanced through the addition of Tute Genomics’ constitutional and exome testing capabilities. The integrated offering will provide a single clinical platform for clinical workflow support of somatic cancer and constitutional testing.
PierianDx will maintain the Tute Genomics solution until the platforms are fully integrated into CGW 6.0 in the spring of 2017.
As part of the transaction, Reid Robison, CEO of Tute, will join PierianDx’ Board of Directors and Tute COO Andy Olson and Vice President of Product Development Bryce Daines will immediately relocate to St. Louis. PierianDx will maintain a development team in Provo, Utah.
Led by CEO Ted Briscoe, PierianDx enables health systems, academic medical centers and commercial labs to deliver patient-specific diagnosis and treatments based on an individual’s DNA. In use since 2011, and regularly enhanced with new patient, clinical and research data, its proprietary Clinical Genomicist Workspace (CGW) provides clinical labs with analysis, interpretation, and reporting to accelerate their personalized medicine programs.
Co-founded by Dr. Kai Wang and Dr. Reid Robison in 2012, Tute Genomics provides a bioinformatics software platform. In December of 2015, the company acquired the assets of Knome, a human-genome interpretation company co-founded by geneticist and Harvard professor George Church.